DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 01/07/2020 --Osteosarcoma Market Insights, Epidemiology and Market Forecast-2028

(Albany, US) DelveInsight launched a new report on Osteosarcoma Market Insights, Epidemiology and Market Forecast-2028

Some of the key facts of the report
1. Osteosarcoma is a relatively rare tumour of bone with a worldwide prevalence of 3.4 cases per million people per year.
2. Around 800 to 900 new cases of the disease are diagnosed in the United States every year.
3. About 2% of childhood cancers are osteosarcomas, but they make up a much smaller percentage of adult cancers.

Key benefits of the report

1. Osteosarcoma market report covers a descriptive overview and comprehensive insight of the Osteosarcoma epidemiology and Osteosarcoma market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Osteosarcoma market report provides insights on the current and emerging therapies.
3. Osteosarcoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Osteosarcoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Osteosarcoma market.

Request for sample pages

"Osteosarcoma is more prevalent in males when compared to females. Females tend to develop it slightly earlier."

In the current market scenario, the standard Osteosarcoma treatment includes Surgery, Chemotherapy and Radiation therapy. Osteosarcoma treatment relies on a combination of therapies that covers surgery, chemotherapy and radiation therapy. Chemotherapy such as doxorubicin, cisplatin, high-dose methotrexate, and ifosfamide have antitumor activity in Osteosarcoma.

Even though various Chemotherapies are available, but these therapies may cause adverse effects, and limited knowledge of the pathogenesis of Osteosarcoma is available. So, these limitations have led to an urgent demand for more advanced novel therapies to treat Osteosarcoma. However, tremendous efforts have been made to define the biology of Osteosarcoma in the hopes of developing molecular targeting drugs to improve patient outcomes. Several preclinical and clinical agents are currently being investigated for Osteosarcoma. One area of significant research involves using specific agents to target known processes important in Osteosarcoma pathogenesis.

The rising number of Osteosarcoma patients, increasing awareness, and increasing research and development activities are a few of the factors that are anticipated to contribute towards the Osteosarcoma market growth during the forecast period (2018-2028).

The launch of the emerging therapies is expected to significantly impact the Osteosarcoma treatment scenario in the upcoming years:-
Drugs covered
1. Inhaled lipid-complexed cisplatin
2. ABI-009
3. CLR 131
And many others

The key players in Osteosarcoma market are:
1. Eleison Pharmaceuticals
2. Aadi Bioscience
3. Cellectar Biosciences

And many others

Table of contents
1. Report Introduction
2. Osteosarcoma Market Overview at a Glance
3. Osteosarcoma Disease Background and Overview
4. Osteosarcoma Epidemiology and Patient Population
5. Osteosarcoma Country- Wise Epidemiology
5.1. United States
5.2. EU-5
5.2.1.Germany
5.2.2.France
5.2.3.Italy
5.2.4.Spain
5.2.5.United Kingdom
5.3. Japan
6. Osteosarcoma Treatment & Medical Practices
7. Osteosarcoma Emerging Therapies
7.1. Key Cross Competition
7.2. Inhaled lipid-complexed cisplatin: Eleison Pharmaceuticals
7.3. ABI-009: Aadi Bioscience
7.4. CLR 131: Cellectar Biosciences
8. Osteosarcoma Market Size
9. 7MM Osteosarcoma Country-Wise Market Analysis
9.1. United States
9.2. Germany
9.3. France
9.4. United Kingdom
9.5. Spain
9.6. Italy
9.7. Japan
10. Osteosarcoma Report Methodology
11. DelveInsight Capabilities
12. Disclaimer
13. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight